Research

Area 2

Urological genetics and tumors

Team leader

Strategic objectives

At present, the research group in urological oncology is conducting two main lines of research, based on the two most frequent urological tumors: urothelial and prostate cancer.
The objectives are summarized below:

  1. Identification of molecular markers in the urine of bladder cancer patients, for the non-invasive diagnosis of the disease.
  2. Identification of molecular markers for the noninvasive diagnosis of prostate cancer.
  3. Identification of molecular markers for the prognosis of muscle invading bladder cancer.
  4. Study of the prognostic factors of upper urinary tract tumors.

Main lines of research

  • Microchips for the diagnosis and prognosis of bladder tumors.
  • Identification of micro-RNA for the noninvasive diagnosis of bladder tumors.
  • Determination of disseminated tumor disease in patients with muscle invading bladder cancer, based on evaluation of the genic expression of bladder-specific markers in lymph nodes and peripheral blood.
  • Determination of the genic expression profile associated with treatment response to neoadjuvant chemotherapy with cisplatin and gemcitabine in patients with muscle invading bladder cancer.
  • Study of the prognostic factors of upper urinary tract tumors based on immunohistochemistry and quantitative PCR.
  • Microchips for the diagnosis and prognosis of prostate tumors.
  • Identification of micro-RNA for the noninvasive diagnosis of prostate tumors.